Financials

Financials — What the Numbers Say

Anthem is a small CRDMO (Contract Research, Development and Manufacturing Organization) that punches well above its weight on margins. Revenue compounded at roughly 22% per year over six years to ₹2,124 crore in FY2026, but the real signal sits below the top line: operating margin runs near 39%, ROCE has held above 25% in five of seven years, and the FY2026 cash-flow statement finally proved that the post-IPO capex cycle does turn into real cash. The balance sheet is essentially debt-free with ₹1,007 crore of investments parked against just ₹53 crore of borrowings, which gives management an unusual amount of flexibility for a recently-listed mid-cap. The stock trades at ~74x trailing earnings — a premium that requires the next two years of growth and the FY2023 USFDA-disrupted dip to remain isolated incidents, not the new pattern. The single financial metric to watch is operating margin sustainability into FY2027: at 39-44% the stock is fairly priced; a slip to 30% rewrites the valuation entirely.

1. Financials in One Page

How to read the KPIs.

Operating margin is operating profit divided by revenue — what's left after the cost of doing business but before interest and tax. ROCE (return on capital employed) is EBIT divided by total capital (equity plus debt) — how much profit a rupee of invested capital earns per year; 15% is good, 25%+ is exceptional. FCF margin is free cash flow as a share of revenue — what fraction of every rupee of sales lands in the bank after capex. Debt/equity compares borrowings to shareholder funds — Anthem's 0.02 means the balance sheet is effectively unleveraged. P/E prices earnings: 74x is a premium multiple that demands sustained high growth.

2. Revenue, Margins, and Earnings Power

This section asks: how big is the business, how fast does the top line grow, and how much of each rupee of revenue makes it down to operating profit?

Seven-year revenue and operating profit

Revenue grew from ₹633 crore in FY2020 to ₹2,124 crore in FY2026 — a six-year CAGR of about 22%. The trajectory is not linear. FY2023 saw a 14% revenue decline that management has publicly attributed to delays in USFDA inspections that pushed customer dispatches into the next year. The bounce was sharp: FY2024 grew 34%, FY2025 grew 30%, and FY2026 grew 15%. Net income tracked revenue with one important wrinkle — FY2023 net income actually held up (₹385 crore) despite the revenue drop, because other income jumped to ₹139 crore that year (versus ₹49 crore the year before).

Margin profile

EBITDA margin (earnings before interest, tax, depreciation, and amortization, divided by revenue) is the cleanest read on operating profitability because it strips out capital-structure choices and non-cash charges. Anthem ran at 41-46% EBITDA margin in every year except FY2020 (the pre-scale base year). The decline in operating margin from 46% in FY2022 to 36% in FY2024-2025 looks alarming on first read but is largely a mix story — Anthem absorbed lower-margin commercial work as new product launches scaled, and rebuilt margins back to 39% in FY2026 once those programs moved up the value chain. Management has cited "backward integration" as the structural driver of recent margin improvement.

Recent quarterly trajectory

The quarterly print tells you two things. First, revenue is lumpy — the December-2025 quarter (3Q25) was a noticeable air-pocket at ₹423 crore, dropping 23% sequentially. That single quarter triggered a sell-side downgrade and is the proximate reason for the share-price pullback earlier in FY2027. Second, Q4 FY2026 was the strongest quarter on record on both revenue (₹611 crore) and operating margin (44%) — a meaningful recovery print that re-anchors the full-year picture. Lumpiness is structural for CRDMO companies: large customer programs ship on irregular calendars, and the company has so few clients of consequence that one customer's timing shifts the whole quarter. Investors who underwrite Anthem must accept this volatility.

3. Cash Flow and Earnings Quality

This section asks the most important quality question: do reported profits become cash?

Free cash flow (FCF) is the cash generated by the business after paying for the capital investment required to keep it running. Specifically: cash from operations minus capital expenditure. A high-quality company converts most of its net income into FCF year after year. A low-quality company reports profits that never show up in the bank.

The seven-year picture is bumpy but informative. Anthem covered net income with operating cash flow in five of seven years (FCF/NI above 100% in FY2020 and FY2026). FY2024 was outright bad — FCF turned negative ₹156 crore because operating cash flow collapsed to ₹140 crore while capex stayed elevated at ~₹300 crore to finance the Harohalli Unit-II capacity build. That was the single year the financials told a different story than the income statement. The FY2026 print resolves the doubt: ₹844 crore of operating cash flow against ₹592 crore of net income (CFO/NI = 143%) and a record ₹637 crore of FCF. The capex cycle has crested and working capital — particularly inventory days — has normalized.

Where the cash actually came from and went

Line item (₹ cr)	FY2024	FY2025	FY2026	What it tells you
Cash from operations	140	418	844	Underlying business cash generation; FY24 was a working-capital absorption year
Capex (CFI - investments)	~296	306	207	Capex peaked in FY24-25 during Unit-II expansion; FY26 normalizing
Free cash flow	-156	154	637	Net of capex — FY26 step-change is the key positive read
CFO / EBITDA	24%	67%	87%	Cash conversion of operating profit — FY26 is finally clean
Working capital days	128	134	207	Headline rose, but inventory days collapsed from 167 to 56

The cash conversion cycle (debtor days plus inventory days minus payable days) went from 202 days at the end of FY2025 to 124 days at the end of FY2026 — a 78-day improvement driven by inventory clearing. Investors should note that the "working capital days" line on Screener moved the other way (134 to 207) because that metric includes other working capital items and timing effects; the cash conversion cycle is the cleaner read.

4. Balance Sheet and Financial Resilience

This section asks: does the balance sheet add flexibility (cash, low debt, liquid investments) or risk (leverage, working-capital trap, intangible asset bloat)?

The Anthem balance sheet has three things going for it. First, equity grew from ₹421 crore in FY2020 to ₹3,042 crore in FY2026 — driven almost entirely by retained earnings until the FY2026 IPO event swelled investments. Second, total borrowings sit at ₹53 crore against ₹3,042 crore of equity — a debt/equity ratio of 0.02. Third, investments climbed to ₹1,007 crore in FY2026, more than 19x outstanding debt. Anthem is essentially a net-cash company.

Leverage and coverage

EBITDA interest coverage was already healthy in FY2020 at 12x and is now 138x — a number so large it has stopped being financially meaningful. The IPO repaid the modest legacy borrowings and the cash flowing in raised the cash buffer. ICRA reaffirmed Anthem's ratings during FY2025 citing "strong promoter background, robust research and development capabilities… healthy financial profile, strong margins and debt metrics, robust liquidity position."

Working capital — the one bit of friction

Inventory days rose to a worrying 167 in FY2025 before collapsing to 56 in FY2026 — the single biggest working-capital improvement in the series and the proximate cause of the FY2026 cash-flow surge. Debtor days have crept up to 101, which is consistent with a CRDMO model selling to large pharma customers on extended payment terms. Payable days fell to 34, which means Anthem is paying suppliers faster than collecting from customers — typical for a younger CRDMO without bargaining leverage upstream.

5. Returns, Reinvestment, and Capital Allocation

This section asks: does each rupee of capital invested in the business earn an attractive return, and how is management spending the cash?

Returns on capital

ROCE (return on capital employed) is EBIT divided by total capital, capturing how productively the business uses every rupee invested regardless of how that rupee was financed. ROE (return on equity) is the same idea but for equity holders specifically. ROA (return on assets) measures profitability against total assets.

ROCE has compressed from a stratospheric 55% in FY2021 to 30% in FY2026 — but a 30% ROCE is still in the top decile of Indian industrials, and the compression is the direct result of equity buildup (₹1,355 crore in FY22 to ₹3,042 crore in FY26) outpacing operating-profit growth as the company capitalized for the next leg. ROE at 19.5% in FY2026 is below the FY21 spike (38.7%) but still well above the cost of equity for an Indian healthcare name (~13-14%).

Capital allocation — where the cash went

Anthem has not paid a dividend or bought back stock — every rupee of free cash has been ploughed back into the business or used to repay borrowings. Cumulative capex over the last three years (FY24-FY26) was ₹767 crore, financing the Unit-II Harohalli capacity ramp. With FCF now running at ₹637 crore annually and the capex cycle moderating, the question for FY2027 is whether management initiates a maiden dividend or maintains the all-reinvestment policy. The recent IPO was an offer-for-sale (no fresh capital raised), so existing investments and FY26 cash flow are the entire funding source for the next leg.

Per-share economics

EPS on a post-split, post-bonus basis has grown from ₹6.75 in FY2023 to ₹10.54 in FY2026 — a 16% three-year CAGR, broadly in line with net-income growth on a steady share count near 56 crore shares. Dilution has been negligible (the IPO was an OFS, not fresh issuance).

6. Segment and Unit Economics

The segment.json file is empty for Anthem (the data provider had no segment break for this name at the time of fetch). The most useful unit economics we can reconstruct come from management's RHP disclosures and recent transcripts.

Reported segments (per IR materials): Anthem operates two segments — (1) CRDMO services (the core contract research/development/manufacturing business), and (2) Specialty Ingredients (fermentation-derived probiotics, enzymes, nutraceuticals, vitamin analogues). Management disclosed in pre-IPO materials that CRDMO represents roughly 80%+ of revenue with Specialty Ingredients the remainder.

Geographic mix (per RHP): Exports drive the franchise — approximately 70-75% of revenue is dollar-denominated, primarily into the US and EU regulated markets, with the balance from domestic and emerging-market customers. The export tilt explains why Anthem benefits from a weaker rupee but also why its operating-margin trajectory is sensitive to USD/INR and to USFDA inspection cadence.

The absence of a clean segment.json is a data gap, not a business gap. The investor question to ask once full segment financials are filed is: does Specialty Ingredients dilute or accrete CRDMO margin? Current peer evidence suggests Specialty Ingredients runs at lower margin than CRDMO contract revenue, but at higher revenue visibility — a mix story that could explain part of the year-to-year operating-margin volatility.

7. Valuation and Market Expectations

This is where the page earns its keep. What does the current ₹780 share price actually imply?

Trading multiples — Anthem versus its own history (limited)

Anthem only listed in July 2025, so a long-history valuation chart does not exist. The IPO priced at a P/E of 70.6x trailing FY2025 earnings, and the stock listed at a 27% premium (₹723 on day one). Today's ₹780 print and trailing FY2026 EPS of ₹10.54 work out to roughly 74x trailing P/E.

Anthem trades at roughly twice the trailing multiple of the median listed Indian CRDMO. The premium is defensible on two grounds: (1) Anthem's operating margin is ten-plus percentage points above peer median, and (2) its ROCE is the best in the listed set. The premium is questionable on one ground: the FY2023 revenue decline shows the business is not immune to inspection-cycle risk that can wipe out a year of growth, and that risk is not priced into 74x earnings.

Bear / Base / Bull valuation framework

Sell-side coverage today maps to the base case. JPMorgan rates Anthem Buy with a ₹790 target (Feb 2026 upgrade), Nomura/Instinet initiated coverage in Nov 2025 with a Buy and ₹740 target. The average street price target sits in a tight ₹740-790 band — essentially fair value to current price, leaving the stock priced for solid base-case execution and little margin for error.

Multiples-based fair-value calls (third-party)

Two independent valuation services price Anthem below the current market: Alpha Spread's Multiples-Based Value comes out at ₹540 (31% downside), and their Relative Value at ₹539 (17% downside). These models compare Anthem to broad peer averages without crediting its margin and ROCE premium, so a discount versus those benchmarks is expected. Take them as an outer-bound bear-case check, not a target.

8. Peer Financial Comparison

Using the latest available period for each peer (FY2026 for Anthem, Syngene, Sai Life, Cohance, Piramal Pharma; FY2025 for Divi's).

Anthem sits in the top-right corner of the peer plot — the only listed Indian CRDMO with both 39%+ operating margin and 30% ROCE. Divi's is the closest economic comparable on profitability (32% margin, 20% ROCE) but trades at a higher P/E (83x) on a much larger revenue base (₹9,360 crore). Syngene is the largest pure-CRDMO peer by revenue but earns only 25% operating margin and 10% ROCE — its multiple looks "cheap" at 59x P/E but the underlying economics are weaker. Piramal Pharma is the cautionary tale: similar revenue to Divi's but lost money in FY2026 (net loss ₹326 crore) under the weight of debt (debt/equity 0.70). The right read is that Anthem's premium multiple is earned by superior margin and capital productivity, but a meaningful slip in operating margin would close that earning quickly.

9. What to Watch in the Financials

Closing read

The financials confirm four things: (1) Anthem earns operating margins that no other listed Indian CRDMO can match, (2) the balance sheet is structurally net-cash and gives management strategic flexibility, (3) ROCE has held above 25% in five of seven years which puts the business in the top decile of Indian industrials on capital productivity, and (4) the FY2026 cash-flow print finally validated that the FY2023-2024 capex cycle was investment, not destruction.

The financials contradict the bull narrative on one important point: cash conversion has been inconsistent. FCF was negative in FY2024, weak in FY2025, and only became "good" in FY2026. One strong year does not yet equal a track record. The other contradiction is the FY2023 revenue decline — a 14% drop on USFDA timing shows the business is not immune to single-event risk, and the current 74x trailing P/E does not appear to price that.

The first financial metric to watch is operating margin in Q1 and Q2 FY2027. Two quarters printing 38%+ operating margin on flat-to-up sequential revenue extends the bull case. If Q3 FY26's 37% margin on lower revenue marked customer mix normalising toward lower-margin commercial work, the 74x P/E has no anchor. That single line is the cleanest read on whether to revisit the position.